4 companies in Regeneration, publicly listed.
Longeveron
Longevity · Regeneration · Cell therapy for ageing-related and other conditions
Latest (Oct 26, 2026): Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Open profile →Humacyte
Regeneration · Bioengineered human tissue
Latest (Sep 22, 2026): Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Open profile →Lineage Cell Therapeutics
Regeneration · Replacement cell therapies
Latest (Aug 6, 2026): LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Open profile →Sana Biotechnology
Gene & cell engineering · Regeneration · Engineered cells as medicines
Latest (Aug 10, 2026): Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.